Pituitary
Gonadotropin-Releasing Hormone receptors (
GnRH-R) mediate the activity of the hypothalamic decapeptide
GnRH, thus playing a key role in the regulation of the reproductive axis. Early-stage
prostate cancer (PCa) is dependent on serum
androgen levels, and
androgen-deprivation
therapy (ADT), based on
GnRH agonists and antagonists, represents the standard therapeutic approach for PCa patients. Unfortunately, the
tumor often progresses towards the more aggressive
castration-resistant
prostate cancer (CRPC) stage.
GnRH receptors are also expressed in CRPC tissues, where their binding to both
GnRH agonists and antagonists is associated with significant antiproliferative/proapoptotic, antimetastatic and antiangiogenic effects, mediated by the Gαi/cAMP signaling cascade.
GnRH agonists and antagonists are now considered as an effective therapeutic strategy for CRPC patients with many clinical trials demonstrating that the combined use of these drugs with standard
therapies (i.e.,
docetaxel,
enzalutamide,
abiraterone) significantly improves disease-free survival. In this context,
GnRH-based bioconjugates (cytotoxic drugs covalently linked to a
GnRH-based decapeptide) have been recently developed. The rationale of this treatment is that the
GnRH peptide selectively binds to its receptors, delivering the cytotoxic
drug to CRPC cells while sparing nontumor cells. Some of these compounds have already entered clinical trials.